New blood test spots silent liver metastases in pancreatic cancer patients
NCT ID NCT07224802
First seen Jun 27, 2026 ยท Last updated Jun 27, 2026
Summary
This study tested a new blood test that looks for tiny particles (exosomes) released by cancer cells to find early liver spread in people with pancreatic cancer before they have surgery. The goal is to help doctors decide the best treatment plan by identifying patients at high risk of hidden liver metastases. The study involved 372 participants and used machine learning to analyze the blood samples.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
372 people
The number who actually took part.
- Started
-
Jun 2024
- Finished
-
Feb 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients with histologically confirmed pancreatic ductal adenocarcinoma (PDAC) who have undergone curative-intent pancreatectomy with available preoperative plasma samples.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Histologically confirmed pancreatic ductal adenocarcinoma (PDAC) * Undergoing curative-intent pancreatectomy * Availability of preoperative plasma samples * Complete clinical and follow-up data * Written informed consent obtained Exclusion Criteria: * Synchronous or secondary malignancies * Non-adenocarcinoma histology * Lack of informed consent * Incomplete plasma sample data
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Pdac - pancreatic ductal adenocarcinoma are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Medical Center
Duarte, California, 91016, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Two oral drugs join chemotherapy in a bid to shrink pancreatic tumors
- Can a pill duo outsmart a Hard-to-Treat pancreatic cancer mutation?
- Can a simple blood test spot pancreatic cancer early enough to save lives?
- Can a new tracer reveal hidden tumors?
- Can a smart drug home in on Hard-to-Treat GI cancers?
- Could a common diabetes drug boost chemotherapy against pancreatic cancer?